IMPDH1P6: A Potential Drug Target and Biomarker (G392267)

Target Name: IMPDH1P6

NCBI ID: G392267

IMPDH1P6

Other Name(s): inosine monophosphate dehydrogenase 1 pseudogene 6 | Inosine monophosphate dehydrogenase 1 pseudogene 6

IMPDH1P6: A Potential Drug Target and Biomarker

IMPDH1P6 (Inosine Monophosphate Dehydrogenase 1 Pseudogene 6) is a gene that encodes a protein involved in the metabolism of inosine, a nucleotide base that plays a crucial role in various cellular processes. Inosine is produced naturally in the body and is also available as a drug ingredient in some medications. However, changes in the levels of inosine in the body can lead to a range of health problems, including cancer, neurodegenerative diseases, and cardiovascular diseases. As such, targeting the regulation of inosine levels is a promising strategy for the development of new treatments for a variety of diseases.

IMPDH1P6 and Inosine Metabolism

IMPDH1P6 is a key enzyme involved in the metabolism of inosine. Inosine is converted to its active form, inosine monophosphate (IMP), by the action of the enzyme INOSine Monophosphate Dehydrogenase (IMPDH). Once converted to IMP, inosine is used as a template for the synthesis of other nucleotides, including DNA and RNA. Additionally, IMP is also involved in the regulation of various cellular processes, including cell signaling, DNA replication, and cell growth.

IMPDH1P6 and Disease

IMPDH1P6 has been implicated in the development and progression of several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. For example, IMPDH1P6 has been shown to be overexpressed in various cancer types, including breast, ovarian, and colorectal cancers. This increase in IMPDH1P6 activity has been associated with the development of cancer-related symptoms, including increased invasiveness, metastasis, and drug resistance.

IMPDH1P6 has also been implicated in the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to be caused by the build-up of abnormal proteins in the brain. IMPDH1P6 has been shown to be involved in the regulation of neurofibrillary tangles and has been implicated in the development of these conditions.

IMPDH1P6 has also been linked to cardiovascular diseases, including heart failure, hypertension, and stroke. These conditions are characterized by the progressive deterioration of the cardiovascular system and can lead to serious complications or even death. IMPDH1P6 has been shown to be involved in the regulation of cellular signaling processes that are important for cardiovascular function, including the regulation of contractility and the maintenance of blood pressure.

Drug Targeting and Biomarker

The IMPDH1P6 gene is a promising drug target for the development of new treatments for various diseases. By inhibiting the activity of IMPDH1P6, researchers can reduce the levels of inosine in the body and potentially slow down or reverse the progression of diseases associated with high levels of inosine. Additionally, by using IMPDH1P6 as a biomarker, researchers can monitor the effectiveness of drug treatments and determine the potential for new treatments.

IMPDH1P6 has been shown to be a promising drug target for a variety of diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. Further research is needed to fully understand the role of IMPDH1P6 in these conditions and to develop effective treatments. However, by targeting IMPDH1P6, researchers may be able to

Protein Name: Inosine Monophosphate Dehydrogenase 1 Pseudogene 6

The "IMPDH1P6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IMPDH1P6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets